Search

Your search keyword '"Rancati, Francesca"' showing total 13 results
Start Over Author "Rancati, Francesca"
13 results on '"Rancati, Francesca"'

3. High Dose Imatinib Induction Therapy (800 mg/day, 6 Months) In Pre-Treated Chronic Phase CML Patients Improves Cytogenetic and Molecular Responses but Does Not Improve Overall and Progression Free Survival – Final Results of the CELSG Phase III CML11 “ISTAHIT” Trial

Author

Petzer, Andreas L, primary, Fong, Dominic, additional, Lion, Thomas, additional, Dyagil, Irina, additional, Masliak, Zvenyslava, additional, Bogdanovic, Andrija, additional, Griskevicius, Laimonas, additional, Lejniece, Sandra, additional, Goranov, Stefan, additional, Gercheva, Liana, additional, Stojanovic, Aleksandar, additional, Peytchev, Dontcho, additional, Tzetkov, Nikolay, additional, Griniute, Rasa, additional, Oucheva, Radka, additional, Grubinger, Thomas, additional, Kwakkelstein, Marthin, additional, Rancati, Francesca, additional, Gastl, Günther A, additional, and Wolf, Dominik, additional

Published
2010
Full Text
View/download PDF

4. Outcome and Prognosis of 1955 Patients with Chronic Myeloid Leukemia: First Results of the CML-Registry of the European Treatment and Outcome Study EUTOS.

Author

Hasford, Joerg, primary, Rosti, Gianantonio, additional, Lindoerfer, Doris, additional, Baccarani, Michele, additional, Guilhot, Joelle, additional, Montrucchio, Lara, additional, Rancati, Francesca, additional, Simonsson, Bengt, additional, Nicolini, Franck Emmanuel, additional, Ossenkoppele, Gert, additional, and Hehlmann, Ruediger, additional

Published
2009
Full Text
View/download PDF

5. The European Treatment and Outcome Study (EUTOS) for Chronic Myeloid Leukemia (CML). A Prospective, Population-Based European Registry.

Author

Baccarani, Michele, primary, Simonsson, Bengt, additional, Lindörfer, Doris, additional, Rosti, Gianantonio, additional, Almeida, Antonio M, additional, Bogdanovic, Andrija, additional, Clark, Richard E., additional, Colita, Adriana, additional, Costeas, Paul A., additional, Griskevicius, Laimonas, additional, Guilhot, Joelle, additional, Hellmann, Andrzej, additional, Indrak, Karel, additional, Laane, Edward, additional, Labar, Boris, additional, Masszi, Tamas, additional, Lejniece, Sandra, additional, Mayer, Jiri, additional, Ossenkoppele, Gert, additional, Panayiotidis, Panayiotis, additional, Porkka, Kimmo, additional, Saussele, Susanne, additional, Hochhaus, Andreas, additional, Steegmann, Juan Luis, additional, Thaler, Josef, additional, Turkina, Anna, additional, Verhoef, Gregor, additional, Zaritskey, Andrey, additional, Zupan, Irena Preloznik, additional, Rancati, Francesca, additional, Montrucchio, Lara, additional, Hehlmann, Rüdiger, additional, and Hasford, Joerg, additional

Published
2009
Full Text
View/download PDF

6. Imatinib High Dose (800 mg): Results of a Phase II Trial of the GIMEMA (Gruppo Italiano Malattie Ematologiche Dell’Adulto) CML Working Party in Intermediate Sokal Risk Patients and Status-of-the-Art of an Ongoing Multinational, Prospective Randomized Trial of Imatinib Standard Dose (400 mg Daily) vs High Dose (800 mg Daily) in High Sokal Risk Patients.

Author

Rosti, Gianantonio, primary, Castagnetti, Fausto, primary, Amabile, Marilina, primary, Testoni, Nicoletta, primary, Poerio, Angela, primary, Marzocchi, Giulia, primary, Breccia, Massimo, primary, Palandri, Francesca, primary, Intermesoli, Tamara, primary, Stagno, Fabio, primary, Specchia, Giorgina, primary, Abruzzese, Elisabetta, primary, Giannoulia, Panagiota, primary, Saglio, Giuseppe, primary, Pane, Fabrizio, primary, Rancati, Francesca, primary, Nagler, Arnon, primary, Haznedaroglu, Ibrahim, primary, PorkKa, Kimmo, primary, Hjorth-Hansen, Henrik, primary, Nielsen, Johan L., primary, Simonsson, Bengt, primary, Martinelli, Giovanni, primary, and Baccarani, Michele, primary

Published
2006
Full Text
View/download PDF

7. Imatinib Mesylate Can Induce Molecular Complete Remission in Idiopathic Hypereosinophilic Syndrome (HES). A Phase II Multicentric Italian Clinical Trial.

Author

Martinelli, Giovanni, primary, Cilloni, Daniela, primary, Rondoni, Michela, primary, Messa, Francesca, primary, Ottaviani, Emanuela, primary, Gottardi, Enrico, primary, Piccaluga, Pier Paolo, primary, Malagola, Michele, primary, Soverini, Simona, primary, Merante, Serena, primary, Alimena, Giuliana, primary, Bosi, Costanza, primary, De Vivo, Antonio, primary, Rosti, Gianantonio, primary, Giugliano, Emilia, primary, Pane, Fabrizio, primary, Izzo, Barbara, primary, Testoni, Nicoletta, primary, Paolini, Stefania, primary, Rancati, Francesca, primary, Bassan, Renato, primary, Mecucci, Cristina, primary, Baccarani, Michele, primary, and Saglio, Giuseppe, primary

Published
2005
Full Text
View/download PDF

8. Time- and Dose-Response Relationships of Imatinib Mesylate (Glivec) Therapy for Chronic Hypereosinophilic Syndromes.

Author

Bassan, Renato, primary, Acerboni, Sara, primary, Mappa, Silvia, primary, Viero, Piera, primary, Delaini, Federica, primary, Rossi, Giuseppe, primary, Rossi, Valentina, primary, Vannucchi, A., primary, Di Bona, Eros, primary, Ruggeri, Emanuela, primary, Salvi, Anna, primary, Giussani, Ursula, primary, Rancati, Francesca, primary, Intermesoli, Tamara, primary, Rambaldi, Alessandro, primary, and Barbui, Tiziano, primary

Published
2005
Full Text
View/download PDF

9. Imatinib mesylate in the treatment of c-kit–positive acute myeloid leukemia: is this the real target?

Author

Malagola, Michele, primary, Martinelli, Giovanni, additional, Rondoni, Michela, additional, Paolini, Stefania, additional, Gaitani, Stavrula, additional, Arpinati, Mario, additional, Piccaluga, Pier Paolo, additional, Amabile, Marilina, additional, Basi, Constanza, additional, Ottaviani, Emanuela, additional, Candoni, Anna, additional, Gottardi, Enrico, additional, Cilloni, Daniela, additional, Bocchia, Monica, additional, Saglio, Giuseppe, additional, Lauria, Francesco, additional, Fanin, Renato, additional, Visani, Giuseppe, additional, Marrè, Maria Carla, additional, Maderna, Michela, additional, Rancati, Francesca, additional, Vinaccia, Vincenza, additional, Russo, Domenico, additional, and Baccarani, Michele, additional

Published
2005
Full Text
View/download PDF

10. High Dose Imatinib Induction Therapy (800 mg/day, 6 Months) In Pre-TreatedChronic Phase CML Patients Improves Cytogenetic and Molecular Responses but Does Not Improve Overall and Progression Free Survival – Final Results of the CELSG Phase III CML11 “ISTAHIT” Trial

Author

Petzer, Andreas L, Fong, Dominic, Lion, Thomas, Dyagil, Irina, Masliak, Zvenyslava, Bogdanovic, Andrija, Griskevicius, Laimonas, Lejniece, Sandra, Goranov, Stefan, Gercheva, Liana, Stojanovic, Aleksandar, Peytchev, Dontcho, Tzetkov, Nikolay, Griniute, Rasa, Oucheva, Radka, Grubinger, Thomas, Kwakkelstein, Marthin, Rancati, Francesca, Gastl, Günther A, and Wolf, Dominik

Abstract

Abstract 2271

Published
2010
Full Text
View/download PDF

11. High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study.

Author

Petzer AL, Wolf D, Fong D, Lion T, Dyagil I, Masliak Z, Bogdanovic A, Griskevicius L, Lejniece S, Goranov S, Gercheva L, Stojanovic A, Peytchev D, Tzvetkov N, Griniute R, Oucheva R, Ulmer H, Kwakkelstein M, Rancati F, and Gastl G

Subjects
Adolescent, Adult, Aged, Benzamides, Female, Follow-Up Studies, Humans, Imatinib Mesylate, Internationality, Leukemia, Myelogenous, Chronic, BCR-ABL Positive pathology, Male, Middle Aged, Prospective Studies, Remission Induction, Young Adult, Cytogenetic Analysis methods, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Piperazines administration & dosage, Pyrimidines administration & dosage
Abstract

Background: Imatinib 400 mg/day is the standard treatment for patients with chronic phase chronic myeloid leukemia. Recent reports suggested higher and more rapid cytogenetic and molecular responses with higher doses of imatinib., Design and Methods: In this prospective international, multicenter phase III study, 227 patients with pre-treated Philadelphia chromosome-positive, BCR-ABL-positive chronic myeloid leukemia were randomized to a standard-dose imatinib arm (400 mg/day) or a high-dose imatinib arm (800 mg/day for 6 months followed by 400 mg/day as maintenance therapy). In this planned interim analysis hematologic, cytogenetic and molecular responses as well as toxicity were evaluated., Results: Compared to the standard-dose, high-dose imatinib led to higher rates of major and complete cytogenetic responses at both 3 months (major: 21% versus 37%, P=0.01; complete: 6% versus 25%, P<0.001) and 6 months (major: 34% versus 54%, P=0.009; complete: 20% versus 44%, P<0.001). This was paralleled by a significantly higher major molecular response rate at 6 months in the high-dose imatinib arm (11.8% versus 30.4%; P=0.003). At 12 months, the rates of major cytogenetic response (the primary end-point) were comparable between the two arms (57% versus 59%). In contrast to non-hematologic toxicities, grade 3/4 hematologic toxicities were more common in the high-dose arm. Cumulative complete cytogenetic response rates were higher in patients without dose reduction in the high-dose arm (61%) than in the patients with no dose reduction in the standard-dose arm (36%) (P=0.014)., Conclusions: This is the first randomized phase III trial in patients with pre-treated chronic phase chronic myeloid leukemia demonstrating improvements in major cytogenetic response, complete cytogenetic response and major molecular response rates with high-dose imatinib therapy (ClinicalTrials.gov Identifier: NCT00327262).

Published
2010
Full Text
View/download PDF

12. Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study.

Author

Piccaluga PP, Malagola M, Rondoni M, Arpinati M, Paolini S, Candoni A, Fanin R, Messa E, Pirrotta MT, Lauria F, Visani G, Alberti D, Rancati F, Vinaccia V, Russo D, Saglio G, Baccarani M, and Martinelli G

Subjects
Adolescent, Adult, Antineoplastic Agents adverse effects, Benzamides, Disease-Free Survival, Female, Humans, Imatinib Mesylate, Italy, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute mortality, Male, Middle Aged, Piperazines adverse effects, Pyrimidines adverse effects, Survival Rate, Antineoplastic Agents administration & dosage, Drug Resistance, Neoplasm drug effects, Leukemia, Myeloid, Acute drug therapy, Piperazines administration & dosage, Proto-Oncogene Proteins c-kit, Pyrimidines administration & dosage
Abstract

We evaluated safety and efficacy of imatinib (600 mg) in 36 c-KIT+ acute myeloid leukemia patients not amenable to receive conventional chemotherapy. No patient achieved complete remission. One patient obtained a hematologic improvement (platelet increase with transfusion independence). Median overall survival was 3 months (0.5-44+). Non-hematologic toxicity was overall mild.

Published
2007
Full Text
View/download PDF

13. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.

Author

Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S, Tiribelli M, Buccisano F, Testoni N, Gottardi E, de Vivo A, Giugliano E, Iacobucci I, Paolini S, Soverini S, Rosti G, Rancati F, Astolfi C, Pane F, Saglio G, and Martinelli G

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Benzamides, Female, Gene Rearrangement, Humans, Hypereosinophilic Syndrome drug therapy, Imatinib Mesylate, Male, Middle Aged, Oncogene Proteins, Fusion metabolism, Prospective Studies, Protein-Tyrosine Kinases antagonists & inhibitors, Receptor, Platelet-Derived Growth Factor alpha metabolism, Treatment Outcome, mRNA Cleavage and Polyadenylation Factors metabolism, Antineoplastic Agents therapeutic use, Hypereosinophilic Syndrome genetics, Oncogene Proteins, Fusion genetics, Piperazines therapeutic use, Pyrimidines therapeutic use, Receptor, Platelet-Derived Growth Factor alpha genetics, mRNA Cleavage and Polyadenylation Factors genetics
Abstract

Background and Objectives: The hypereosinophilic syndrome (HES) may be associated with the fusion of the platelet derived growth factor receptor a (PDGFRalpha) gene with the FIP1L1 gene in chromosome 4 coding for a constitutively activated PDGFRalpha tyrosine kinase. These cases with FIP1L1-PDGFRalpha rearrangement have been reported to be very sensitive to the tyrosine kinase inhibitor imatinib mesylate., Design and Methods: A prospective multicenter study of idiopathic or primary HES was established in 2001 (Study Protocol Registration no. NCT 0027 6929). One hundred and ninety-six patients were screened, of whom 72 where identified as having idiopathic or primary HES and 63 were treated with imatinib 100 to 400 mg daily., Results: Twenty-seven male patients carried the FIP1L1-PDGFRalpha rearrangement. All 27 achieved a complete hematologic remission (CHR) and became negative for the fusion transcripts according to reverse transcriptase polymerase chain reaction (RT-PCR) analysis. With a median follow-up of 25 months (15-60 months) all 27 patients remain in CHR and RT-PCR negative, and continue treatment at a dose of 100 to 400 mg daily. In three patients imatinib treatment was discontinued for few months, the fusion transcript became rapidly detectable, and then again undetectable upon treatment reassumption. Thirty-six patients did not carry the rearrangement; of these, five (14%) achieved a CHR, which was lost in all cases after 1 to 15 months., Interpretation and Conclusions: All patients meeting the criteria for idiopathic or primary HES should be screened for the FIP1L1-PDGFRalpha rearrangement. For all patients with this rearrangement, chronic imatinib treatment at doses as low as 100 mg daily ensures complete and durable responses.

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results